These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 17609679)

  • 1. Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect.
    Davis JM; Chen N; Glick ID
    Neuropsychopharmacology; 2008 Apr; 33(5):971-5. PubMed ID: 17609679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the efficacy of second-generation antipsychotics.
    Davis JM; Chen N; Glick ID
    Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotics for children and young adults: a comparative effectiveness review.
    Seida JC; Schouten JR; Boylan K; Newton AS; Mousavi SS; Beaith A; Vandermeer B; Dryden DM; Carrey N
    Pediatrics; 2012 Mar; 129(3):e771-84. PubMed ID: 22351885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials.
    Leucht S; Engel RR
    Neuropsychopharmacology; 2006 Feb; 31(2):406-12. PubMed ID: 16123745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between drug company funding and outcomes of clinical psychiatric research.
    Kelly RE; Cohen LJ; Semple RJ; Bialer P; Lau A; Bodenheimer A; Neustadter E; Barenboim A; Galynker II
    Psychol Med; 2006 Nov; 36(11):1647-56. PubMed ID: 16893480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
    Leucht S; Kissling W; Davis JM
    Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
    Gentile S
    J Clin Psychopharmacol; 2007 Feb; 27(1):35-45. PubMed ID: 17224710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001 - 2009).
    Xiang YT; Kreyenbuhl J; Dickerson FB; Ungvari GS; Wang CY; Si TM; Lee EH; Chiu HF; Lai KY; He YL; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong MK; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):500-4. PubMed ID: 22541750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticholinergic use in hospitalised schizophrenic patients in Belgium.
    De Hert M; Wampers M; van Winkel R; Peuskens J
    Psychiatry Res; 2007 Aug; 152(2-3):165-72. PubMed ID: 17445906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quetiapine has a direct effect on the negative symptoms of schizophrenia.
    Tandon R
    Hum Psychopharmacol; 2004 Dec; 19(8):559-63. PubMed ID: 15486960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
    Fusar-Poli P; Kempton MJ; Rosenheck RA
    Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
    Volavka J; Citrome L
    Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.